drug therapy angina
diagnostic
ACS
drug therapy ACS
unstable Angina/NSTEMI
100

Calcium Channel Blockers

uniquely effective for decreasing frequency/severity of spasm

dilate coronary arteries

decreases vascular smooth muscle tone, contractilty, O2 consumption, systemic BP

**not as effective as beta blockers in decreasing myocardial reinfarction

100

pathogenesis of STEMI

coroanry blood flow decreases abruptly 

acute trombus formation d/t atherosclerotic plaque 

thrombogenesis 

*collagen, ADP, epinephrine, serotonin, TXA2, GP 2B/3A, fibrin deposit

100

imbalance of myocardial o2 supply and consumption caused by

atheromatous plaque

coagulation cascade

thrombin genreation

arterial occlusion (partial or complete)

100

drug therapy in ACS (6)

MONA

P2Y12 inhibitors

GP 2B/3A inhibitors

heparin

BB *relieves ischemic chest pain, infarct size, and dysrhytmias 

RAAS inhibitors

*avoid gluccocorticoids and other NSAIDS in patients with STEMI

*restore blood flow in obstructed coronary artery ASAP

100

causes of unstable/NSTEMI

rupture or erosion if coronary plaque

*thrombosis

dynamic obstruction due to vasoconstriction

*prinzmetal- variant angina, cold, cocaine use

worsening coronary luminal narrowing due to progressive atherosclerosis, in -stent restonosis, narrowing of CABGs

inflammation (vasculitis)

myocardial ischemia due to increased O2 demand

*sepsis, fever, tachycardia, anemia

200

ACE inhibitors

treats HTN, heart failure, cardioprotective

prevents ventricular remodeling, stabilizes electrical acitivity of re-perfused heart and prevent occurance of reperfusion arryhtmias

reduce myocardial workload and decrease myocardial O2 demand

200

defining diagnosis of Myocardial infarction

rise or fall of cardiac markers (troponin) AND at least

* symptoms of ischemia

* ECG changes (ST changes, new LBBB)

* Q waves on ECG

* imaging evidence of new loss of vialable myocardium or new regional wall abnormality 

*angiography identifying intracoronary thrombus

200

no ST segment elevation

positive troponins

NSTEM -> myocardial infarction

200

reperfusion therapy

thrombolytic therapy with tPA , streptokinase, within 30-60 minutes of hospital arrival and within 12 hrs of symptoms onset

*restores antegrade blood flow in occluded coronary artery

200

presentation

angina at rest lasting > 10 minutes

chronic angina pectoris - a crescendo pattern - increasing in intensitiy, duration, frequency

new-onset angina that is severe, prolonged, or disabling

300

statins

coronary plaque stabilization

decreases lipid oxidatoin, inflammation, matrix metalloproteinase, cell death

reduces mortality of noncardiac surgery and vascualr surgery

300

troponin

increase within 3 hours after myocardial injury

remain elevated for 7-10 days

*more specific than CK-MB

*the greater the level of troponin the larger the MI

300

no ST elevation

negative troponins

unstable angina

300

PCI

indications

treatment

severe HF and/or pulmonary edema

symptoms present for 2-3 hours

mature clot (less likely to be lysed by fibrinolytic)

contraindications to thrombolytic therapy

*coronary stents and antiplatelet drugs

300

treatment of NSTEMi

bed rest, O2, analgesia, BB therapy, subligual or IV nitro, CCB, ASA, P2Y12 inhibitors, heparin

thrombolytic therapy not indicated

400

revascularization

indicated for failure of medical therapy

>50% occlusion of L main coronary

>70% stenosis of epicardial coronary artery

imparied EF < 40%

400

imaging studies

patients with a typical ECG evidence of AMI do not need an echo

useful in patients with LBBBB or abnormal ECG in whom AMI is uncertain

regional wall motion abnormalities in most patietns with AMI

400

ST segment elevation

positve troponins

STEMI -> myocardial infarction

400
emergent CABG

restore blood flow in occluded coronary artery

emergent CABG - indicated anatomy that inhibtis PCI, failed angioplasty, evidence of infarction related ventricular septal rupture or mitral regurgitation

500

CABG > PCI

CABG is preferred over PCI in patients with significant left main coronary artery disease 

- 3 vessel CAD

-DM with 2-3 vessel CAD 

500

DAPT (dual - antiplatelet therapy)

ASA with P2Y12 inhibitor

minimum 2 weeks - balloon angioplasty without stenting

minimum 6 weeks - bare metal stent

mimimum 1 year - drug - eluting stent

500

surgery interval

time to wait for elective surgery

*balloon angioplasty no stent 2-4 weeks

*bare-metal stent: 30 days to 12 weeks

*CABG: 6 weeks - 12 weeks

*drug eluding stent: 6 months - 12 months

neuraxial is not encourgaged in patietns who are receiving DAPT

500

PCI

alternative to CABG

balloon angioplasty, bare metal stent, drug - eluding stent

angioplasty may cause vessel injurt - destruction of endothelium making areas prone to thrombosis

risks - bleeding, thrombosis